Literature DB >> 12820385

Endostatin inhibits migration and invasion of head and neck squamous cell carcinoma cells.

Ralph F Wilson1, Mark A Morse, Ping Pei, Robert J Renner, David E Schuller, Fredika M Robertson, Susan R Mallery.   

Abstract

Head and neck cancers are significant due to their high morbidity and associated complications. We report, for the first time, that endostatin directly affects epithelial lineage human cells derived from tumors of patients with head and neck squamous cell carcinoma (HNSCC). This study investigated endostatin's effects on several HNSCC cellular functions that are essential for tumor progression. We determined that exposure of HNSCC cells to endostatin activated the transcription-activating factors, NF-xB and AP-1 in a cell-line-dependent fashion. Endostatin also down-regulated the gene expression of several pro-migratory molecules. Migration and invasion assays showed that endostatin significantly inhibited these functions that are essential for tumor progression. Fluorescent labeling studies showed endostatin co-localized to tropomysin-binding HNSCC the microfilaments, suggesting endostatin's suppression of HNSCC cell migration and invasion may reflect perturbation of the microfilament function. Our data imply that endostatin's clinical efficacy extends beyond angiostatic properties to encompass a direct anti-tumorigenic effect against HNSCC cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12820385

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Recombinant human collagen XV regulates cell adhesion and migration.

Authors:  Merja Hurskainen; Florence Ruggiero; Pasi Hägg; Taina Pihlajaniemi; Pirkko Huhtala
Journal:  J Biol Chem       Date:  2009-12-29       Impact factor: 5.157

2.  Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF.

Authors:  Meng Tong; Brandon Lloyd; Ping Pei; Susan R Mallery
Journal:  J Cell Biochem       Date:  2008-12-01       Impact factor: 4.429

3.  Reduced nonprotein thiols inhibit activation and function of MMP-9: implications for chemoprevention.

Authors:  Ping Pei; Michael P Horan; Russ Hille; Craig F Hemann; Steven P Schwendeman; Susan R Mallery
Journal:  Free Radic Biol Med       Date:  2006-07-15       Impact factor: 7.376

4.  The radiosensitization effects of Endostar on human lung squamous cancer cells H-520.

Authors:  Zhen Y You; Yong Zhao; Feng Liu; Ying D Zhang; Jun J Wang
Journal:  Cancer Cell Int       Date:  2010-05-24       Impact factor: 5.722

5.  Inherent phenotypic plasticity facilitates progression of head and neck cancer: endotheliod characteristics enable angiogenesis and invasion.

Authors:  Meng Tong; Byungdo B Han; Andrew S Holpuch; Ping Pei; Lingli He; Susan R Mallery
Journal:  Exp Cell Res       Date:  2013-01-29       Impact factor: 3.905

6.  Enhancement of recombinant human endostatin on the radiosensitivity of human pulmonary adenocarcinoma A549 cells and its mechanism.

Authors:  Xiao-dong Jiang; Yun Qiao; Peng Dai; Qin Chen; Jin Wu; Da-an Song; Shi-qiu Li
Journal:  J Biomed Biotechnol       Date:  2012-06-18

7.  Serum endostatin levels are elevated in colorectal cancer and correlate with invasion and systemic inflammatory markers.

Authors:  T Kantola; J P Väyrynen; K Klintrup; J Mäkelä; S M Karppinen; T Pihlajaniemi; H Autio-Harmainen; T J Karttunen; M J Mäkinen; A Tuomisto
Journal:  Br J Cancer       Date:  2014-08-19       Impact factor: 7.640

8.  Type XVIII collagen degradation products in acute lung injury.

Authors:  Gavin D Perkins; Nazim Nathani; Alex G Richter; Daniel Park; Murali Shyamsundar; Ritva Heljasvaara; Taina Pihlajaniemi; Mav Manji; W Tunnicliffe; Danny McAuley; Fang Gao; David R Thickett
Journal:  Crit Care       Date:  2009-04-09       Impact factor: 9.097

9.  Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope?

Authors:  Aini Hyytiäinen; Wafa Wahbi; Otto Väyrynen; Kauko Saarilahti; Peeter Karihtala; Tuula Salo; Ahmed Al-Samadi
Journal:  Front Oncol       Date:  2021-06-14       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.